No Data
No Data
ADR Japan Stock Ranking~ Overall, buy dominance in companies like Japan Post, with Chicago at 39,375 yen, 415 yen higher than Osaka.
Japanese stocks of American Depositary Receipts (ADR), based on Tokyo Stock Exchange comparison (calculated at 1 dollar to 148.22 yen), Japan Post <6178>, Mitsubishi Corp <8058>, Toyota Industries <6201>, Mizuho Financial Group <8411>, Mitsubishi Electric Corp. unsponsored ADR <6503>, SoftBank Group <9984>, Tokyo Electron <8035>, etc., are rising, with overall buying dominance. Chicago Nikkei 225 futures settlement price is 415 yen higher than Osaka daytime at 39,375 yen. The US stock market rebounds. Dow Inc. average rises 126.13 dollars to 42,080.
Express News | GSK, Pfizer And Shionogi-owned ViiV Healthcare Will Make At Least 2M Doses Of Long-Acting Cabotegravir For HIV Pre-exposure Prophylaxis Available For Procurement For Low- And Middle-Income Countries During 2025-2026, Tripling From 2024
Anjes Research Memo (2): A biotech venture launched by universities in Osaka specializing in the development of gene medicine
AnGes <4563> is a bio-venture established in 1999 from Osaka University, aiming to commercialize the research results of angiogenesis effects through the administration of HGF gene (Hepatocyte Growth Factor).
Sysmex, Konami Group, etc. (additional) Rating
Upgrade - Bullish Code | Stock Name | Securities Company | Previous | After | ------ | --------------- | ---------- | -------------- | -------------- | <7276> | Komatsu Seiko | Mizuho | 'Hold' | 'Buy' | Downgrade - Bearish Code | Stock Name | Securities Company | Previous | After | ----
Japanese Shares Drop as Investors Seek Safety Amid Middle East Tensions
October 1st [Today's investment strategy]
[Fisco Selected Stocks] [Material Stocks] Nexera Pharma <4565> 1226 yen (10/1) Drug discovery venture. Former Sosei Group. Its subsidiary Nexera Pharma Japan has announced the signing of a partnership agreement with Shionogi <4507> regarding the distribution and sales of the insomnia treatment drug "Cubick Tablets" in Japan, and resolved its sales efforts with Mochida Pharmaceutical <4534>. Shionogi will independently conduct distribution and sales activities in Japan. [Emerging Markets]
No Data
No Data